Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen
Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

We are at the beginning of a remarkable age of technical and clinical alchemy.



MEDIA 7: You have had a profound professional career of over 30 years, could you please share a glimpse of your wonderful journey?
MATTHEW SAPPERN:
My career has been anything but a straight line. I actually started in the media industry and thirty years later I am fortunate to be leading a team of mission-driven healthcare professionals and technologists, making what I believe is a profound difference in the lives of mothers and babies. I have benefitted from proximity to talented, brilliant people just about everywhere I have worked.


M7: What are your thoughts on the penetration of ‘Artificial Intelligence’ in the healthcare domain and what changes do you see happening in the near future?
MS:
AI is still a nascent idea in healthcare, limited by quality data and by clinical acceptance. This will change over time. The sheer number of patients vs healthcare workers present challenges of scale and resultingly open the door to automation of all types. In my experience, I have come to believe that machine learning technologies can and should play a critical part in augmenting, not replacing, current clinical care. These tools can reduce the amount of subjectivity and variability in the assessment and delivery of care and reduce clinical bias and normalization of deviance which have a negative impact on the quality of care.


Machine learning technologies can and should play a critical part in augmenting, not replacing, current clinical care.



M7: PeriGen’s mission is ‘Protect Moms and Babies.’ To what extent has PeriGen’s AI patient safety platform improved the ‘Labor and Delivery’ healthcare?
MS:
PeriGen solutions use AI tools to augment subjective assessments with objective, data-driven assessments. More than half the adverse events in term births are preventable and studies show a prevalence of delayed recognition and response to clinical warning signs. In L&D, a single nurse is typically the arbiter of how a mother or fetus is tolerating labor and that can be dangerous. Variation in experience, training, clinical bias, and normalization of deviance all challenge that nurse as she strives to make the right call, and to effectively communicate her clinical assessments to the rest of the care team. 


M7: Could you please give us an insight about the upcoming ‘@AWHONN Virtual Conference’ and what message does it hold for the attendees?
MS:
I don’t have much insight other than I think everyone was hoping to get together in person, but safety has to come first. I am sure the decision to go virtual was difficult but governed by concern for the nursing constituency.


In short: find smart, committed people and pave their way.



M7: You have led PeriGen through a period of innovation and growth as well as multiplied its market share and revenue. Would you like to share some of your preferred strategies behind this success?
MS:
For the last decade I held fast to the fundamental view that technology should be helping nurses manage in an increasingly challenging clinical environment. I never wavered from this view. I then surrounded myself with brilliant people, made sure they understood and believed in the mission, and did my best to listen and move obstacles to let these brilliant people do their thing. In short: find smart, committed people and pave their way.


M7: What advice would you like to give our readers starting their careers in this sector?
MS:
I believe we are at the beginning of a remarkable age of technical and clinical alchemy, so your timing is perfect. Always maintain a great respect for the healthcare providers you work with because the secret is to design great technology that these amazing people want to use.

ABOUT PERIGEN

PeriGen is the global leader in applying AI to perinatal care. It is the only technology company deploying FDA-cleared AI algorithms at the bedside, its software has been featured in numerous peer-reviewed publications and has been shown to help health systems significantly reduce unanticipated NICU transfers.

More C-Suite on deck

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Q&A with Paula Muto, Founder and CEO of UBERDOC Inc.

September 6, 2021

Paula Muto, M.D., F.A.C.S., Founder and CEO of UBERDOC, is also the Director of the Vein Center at Mutosurgical. A graduate of Amherst College and New York Medical College, Dr. Muto is a fellowship-trained vascular surgeon by specialty who also practices general surgery. Paula is an advocate of disruption in healthcare and speaks passionately on many issues regarding transparency in healthcare, patient rights, and ensuring patient access to the care they need and deserve.

Read More

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Q&A with Paula Muto, Founder and CEO of UBERDOC Inc.

September 6, 2021

Paula Muto, M.D., F.A.C.S., Founder and CEO of UBERDOC, is also the Director of the Vein Center at Mutosurgical. A graduate of Amherst College and New York Medical College, Dr. Muto is a fellowship-trained vascular surgeon by specialty who also practices general surgery. Paula is an advocate of disruption in healthcare and speaks passionately on many issues regarding transparency in healthcare, patient rights, and ensuring patient access to the care they need and deserve.

Read More

Related News

HEALTHTECH SECURITY

Carrum Health Raises $45 Million Series B to Expand Cancer Care Offerings and Launch New Service Lines

PRnewsiwire | June 05, 2023

Carrum Health today announced an oversubscribed $45 million Series B financing led by OMERS Growth Equity. Revelation Partners joined the round along with return investors Tiger Global, Wildcat Venture Partners, Cross Creek and SpringRock Ventures. Carrum Health will use the funding to expand its growing oncology benefit offerings and scale its surgical care service lines to give employees access to the top 10% of doctors and providers across the country while helping employers control healthcare spending. Teresa Lee, managing director of OMERS Growth Equity, will join Carrum Health's board of directors. "We are very excited to partner with Carrum Health, a pioneering and differentiated player in the healthcare space, that offers an innovative, scalable approach in the shift to value-based care. With its Centers of Excellence (COE) network, digital platform and data-driven surgical episode bundling capabilities, Carrum Health has created a solution that allows for real-time and measurable value to employers, as well as a superior patient and clinician experience," said Lee. "The company is well-positioned to transform how healthcare is delivered and paid for, and we look forward to supporting the management team in realizing that vision." Carrum Health's unique value-based program addresses acute care scenarios, such as orthopedic surgery and cancer treatment, which accounts for nearly half of total employer spend. Carrum Health's COE solution not only reduces unnecessary procedures by as much as 30%, leading to better patient outcomes, it can result in savings of up to 45% per care episode, according to a published study by the RAND Corporation. "Every business in America is looking to manage costs, but they can't afford to sacrifice the benefits they offer employees. Carrum Health firmly believes that the path to reducing healthcare costs starts with delivering higher quality care," said Carrum Health CEO Sach Jain. "Our COE solution is proven to deliver significant savings on healthcare spend and generate measurable cost savings within the first year of deployment. In a time when employers are looking to consolidate benefits, we've seen 100% year-over-year growth in new customers and zero churn of existing customers." Carrum Health has seen formidable momentum with its pioneering oncology COE offering and currently partners with top cancer care providers across the country, including AccessHope LLC, City of Hope, GRAIL LLC, Memorial Sloan Kettering Cancer Center and University of Chicago Medicine. In 2022 alone, the company added six new partners, including CVS, Included Health, Accolade, Rightway, SWORD Health and Virgin Pulse. About Carrum Health Carrum Health is a value-based healthcare platform delivering higher quality care while helping self-funded employers immediately reduce their spend for the most prevalent and costly conditions including cancer, musculoskeletal, cardiovascular, and bariatric. Utilizing a Centers of Excellence (COE) network, with an all-inclusive pricing model and 30-day warranty on care, Carrum members receive surgical and cancer treatment guidance and coordination through the entire care journey with upfront pricing, ensuring the highest quality, most appropriate care. Carrum reduces unnecessary procedures by as much as 30% and aligns cost and care incentives to save employers up to 45% per episode of care, all validated by peer-reviewed publications. Carrum's award-winning technology gives members access to a mobile app and Care Specialist that guides them through the surgery process, and a seamless platform integration to make COE adoption plug-and-play for employers. Backed by OMERS Growth Equity and Tiger Global, Carrum was named to the 2021 CB Insights Digital Health 150 and named one of the best places to work in 2022 by Built In. The company, founded in 2014, is headquartered in Silicon Valley.

Read More

HEALTH TECHNOLOGY

Apollo Launches Next-Generation Platform for Rapid Insights in Healthcare and Life Sciences

Businesswire | June 01, 2023

Apollo Intelligence (Apollo), a leading provider of real-time global data and insights to the healthcare and life science industries, announces the launch of its next-generation market insights technology platform to support rapid insights and data collection in the healthcare and life science industries. The advanced platform is fueled by the company’s ongoing investments in its core technologies, propelled by machine learning (ML) and artificial intelligence (AI). With a modern enterprise data architecture, built from best-in-class technologies, Apollo’s next-generation platform provides customers with advanced capabilities to support their progressive insight and data needs. The platform uses ML sampling intelligence to reach global healthcare professional (HCP) panelists with higher efficiency, offering the right research opportunities to the right HCP stakeholders, at the right place and time. This new, advanced capability fosters a seamless cycle of targeted interaction and ongoing engagement that enables greater speed-to-insight and higher quality data. For HCPs, Apollo’s enhanced routing capabilities mean they receive more relevant and matched opportunities to share their expertise and amplify their voice. Capabilities currently rolling out in beta include natural language processing (NLP) advancements in open text analysis for tagging, coding, ML-enhanced adverse event (AE) detection, and reporting. ML-based honoraria optimization for panel engagement. dynamic profiling and validation. In the second half of 2023, these foundational capabilities will support further ML and AI advancements focused on sentiment analysis for free text, survey automation, and expanded global capabilities. “Apollo has been on a multi-year, multimillion-dollar journey building towards this moment when our investments in data and technology would allow us to take advantage of advances in machine learning and data science applications to provide our clients with an unmatched service experience,” said Daniel S. Fitzgerald, president and CEO of Apollo Intelligence. “Life science companies will be able to see the immediate impact in speed and data quality as we leverage machine learning to intelligently sample our HCP communities for data collection. These advances are just the beginning for Apollo as we continue our innovative journey and extend our robust roadmap to deliver higher quality data, speed-to-insight, and advanced analytics and data visualization for our clients.” Apollo has made sizable investments in its platform since 2019 in anticipation of this launch. Its relationship with Frazier Healthcare Partners, in June 2022, has accelerated investment in these areas, with Frazier and Apollo sharing a vision for technological innovation within the healthcare data and insights market. The Frazier Data and AI Center of Excellence has been an instrumental partner in rapidly advancing these modern elements and realizing Apollo’s technology vision. Apollo Intelligence Apollo’s mission is to accelerate health innovation to improve life. In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry. In 2020, Apollo strengthened its global reach by acquiring Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions. Apollo provides access to 2 million healthcare stakeholders worldwide—including physicians, patients, caregivers, and allied healthcare professionals. Apollo’s 250+ employees support top global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.

Read More

DIGITAL HEALTHCARE

CarepathRx Health System Solutions and Evernorth Health Services Forge Strategic Partnership to Enhance Specialty Care for Patients

PRNewswire | June 02, 2023

CarepathRx Health System Solutions, a CarepathRx company and portfolio company of Nautic Partners (Nautic), and Evernorth Health Services, a subsidiary of The Cigna Group announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions, and health system relationships to improve, expand, and accelerate pharmacy care delivery for the growing number of patients with chronic and complex care needs. The CHSS and Evernorth partnership will deliver integrated specialty pharmacy care to CHSS' growing base of 600-plus hospitals, health systems, and physicians – helping diversify the services they offer to best support patients. This includes enhanced coordinated infusion services, virtual care capabilities, value-based care arrangements, and site of care flexibility. Evernorth's expansive suite of services, including Accredo's specialty care and pharmacy expertise and CuraScript SD's specialty medication distribution across 12,000 physicians, is highly complementary to CHSS' capabilities that help health systems expand in-house specialty pharmacies, infusion and polypharmacy services. "Forging deeper relationships with physicians and other specialty and infusion pharmacies – a critical point of care for people with chronic and complex needs – is a key priority as we work to increase access to care and improve affordability," said Eric Palmer, President and CEO, Evernorth. "Specialty care continues to be a focal point for hospital, health system, and physician partners, and our collaboration with CHSS is an important step in delivering on our commitment to bring them even more patient care services to improve overall outcomes." Together, over time, CHSS' and Evernorth's expertise will help enable simpler, faster connections to care for patients managing chronic and complex specialty conditions. As many of these patients need specialty or acute drug therapies, the partnership will focus on continuity of care for specialty drugs, management of infusion services across sites of care – from ambulatory to physician office to home settings – and value-based site-of-care strategies. The intent is to drive optimal patient treatment plans and deepen physician engagement, resulting in better patient experiences, more care extensions, and greater affordability. "At CarepathRx, we believe health systems, hospitals, and physicians play the most important roles in providing the best care to patients with chronic and complex diseases," said John Figueroa, Chairman and CEO, CarepathRx. "Through specialty and infusion pharmacy partnerships, CHSS has created a model for health systems to extend their reach to alternate sites of care and into the home. This partnership with Evernorth is truly unique and will accelerate CHSS' mission by creating payer-physician connections and leveraging Evernorth's specialty and care services." Centerview Partners acted as lead financial advisor and Cantor Fitzgerald is also acting as financial advisor to CarepathRx and Nautic. Kirkland & Ellis LLP acted as legal advisor to CarepathRx and Nautic. Greenhill & Co. acted as financial advisor to Evernorth. Wachtell, Lipton, Rosen & Katz and Quarles & Brady LLP acted as legal advisors to Evernorth. About CarepathRx CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical, quality, and financial results. Through the industry's most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient's complete healthcare journey. The company takes an enterprise approach, providing a powerful combination of technology, market-leading clinical pharmacy services, and wrap-around services that optimize pharmacy performance across the enterprise for fully integrated pharmacy operations, expanded healthcare services, improved ambulatory access, minimized clinical variation, and new health system revenue streams. Today, CarepathRx serves more than 25 health systems and 600 hospitals, with more than 1,500 employees nationwide.

Read More

HEALTHTECH SECURITY

Carrum Health Raises $45 Million Series B to Expand Cancer Care Offerings and Launch New Service Lines

PRnewsiwire | June 05, 2023

Carrum Health today announced an oversubscribed $45 million Series B financing led by OMERS Growth Equity. Revelation Partners joined the round along with return investors Tiger Global, Wildcat Venture Partners, Cross Creek and SpringRock Ventures. Carrum Health will use the funding to expand its growing oncology benefit offerings and scale its surgical care service lines to give employees access to the top 10% of doctors and providers across the country while helping employers control healthcare spending. Teresa Lee, managing director of OMERS Growth Equity, will join Carrum Health's board of directors. "We are very excited to partner with Carrum Health, a pioneering and differentiated player in the healthcare space, that offers an innovative, scalable approach in the shift to value-based care. With its Centers of Excellence (COE) network, digital platform and data-driven surgical episode bundling capabilities, Carrum Health has created a solution that allows for real-time and measurable value to employers, as well as a superior patient and clinician experience," said Lee. "The company is well-positioned to transform how healthcare is delivered and paid for, and we look forward to supporting the management team in realizing that vision." Carrum Health's unique value-based program addresses acute care scenarios, such as orthopedic surgery and cancer treatment, which accounts for nearly half of total employer spend. Carrum Health's COE solution not only reduces unnecessary procedures by as much as 30%, leading to better patient outcomes, it can result in savings of up to 45% per care episode, according to a published study by the RAND Corporation. "Every business in America is looking to manage costs, but they can't afford to sacrifice the benefits they offer employees. Carrum Health firmly believes that the path to reducing healthcare costs starts with delivering higher quality care," said Carrum Health CEO Sach Jain. "Our COE solution is proven to deliver significant savings on healthcare spend and generate measurable cost savings within the first year of deployment. In a time when employers are looking to consolidate benefits, we've seen 100% year-over-year growth in new customers and zero churn of existing customers." Carrum Health has seen formidable momentum with its pioneering oncology COE offering and currently partners with top cancer care providers across the country, including AccessHope LLC, City of Hope, GRAIL LLC, Memorial Sloan Kettering Cancer Center and University of Chicago Medicine. In 2022 alone, the company added six new partners, including CVS, Included Health, Accolade, Rightway, SWORD Health and Virgin Pulse. About Carrum Health Carrum Health is a value-based healthcare platform delivering higher quality care while helping self-funded employers immediately reduce their spend for the most prevalent and costly conditions including cancer, musculoskeletal, cardiovascular, and bariatric. Utilizing a Centers of Excellence (COE) network, with an all-inclusive pricing model and 30-day warranty on care, Carrum members receive surgical and cancer treatment guidance and coordination through the entire care journey with upfront pricing, ensuring the highest quality, most appropriate care. Carrum reduces unnecessary procedures by as much as 30% and aligns cost and care incentives to save employers up to 45% per episode of care, all validated by peer-reviewed publications. Carrum's award-winning technology gives members access to a mobile app and Care Specialist that guides them through the surgery process, and a seamless platform integration to make COE adoption plug-and-play for employers. Backed by OMERS Growth Equity and Tiger Global, Carrum was named to the 2021 CB Insights Digital Health 150 and named one of the best places to work in 2022 by Built In. The company, founded in 2014, is headquartered in Silicon Valley.

Read More

HEALTH TECHNOLOGY

Apollo Launches Next-Generation Platform for Rapid Insights in Healthcare and Life Sciences

Businesswire | June 01, 2023

Apollo Intelligence (Apollo), a leading provider of real-time global data and insights to the healthcare and life science industries, announces the launch of its next-generation market insights technology platform to support rapid insights and data collection in the healthcare and life science industries. The advanced platform is fueled by the company’s ongoing investments in its core technologies, propelled by machine learning (ML) and artificial intelligence (AI). With a modern enterprise data architecture, built from best-in-class technologies, Apollo’s next-generation platform provides customers with advanced capabilities to support their progressive insight and data needs. The platform uses ML sampling intelligence to reach global healthcare professional (HCP) panelists with higher efficiency, offering the right research opportunities to the right HCP stakeholders, at the right place and time. This new, advanced capability fosters a seamless cycle of targeted interaction and ongoing engagement that enables greater speed-to-insight and higher quality data. For HCPs, Apollo’s enhanced routing capabilities mean they receive more relevant and matched opportunities to share their expertise and amplify their voice. Capabilities currently rolling out in beta include natural language processing (NLP) advancements in open text analysis for tagging, coding, ML-enhanced adverse event (AE) detection, and reporting. ML-based honoraria optimization for panel engagement. dynamic profiling and validation. In the second half of 2023, these foundational capabilities will support further ML and AI advancements focused on sentiment analysis for free text, survey automation, and expanded global capabilities. “Apollo has been on a multi-year, multimillion-dollar journey building towards this moment when our investments in data and technology would allow us to take advantage of advances in machine learning and data science applications to provide our clients with an unmatched service experience,” said Daniel S. Fitzgerald, president and CEO of Apollo Intelligence. “Life science companies will be able to see the immediate impact in speed and data quality as we leverage machine learning to intelligently sample our HCP communities for data collection. These advances are just the beginning for Apollo as we continue our innovative journey and extend our robust roadmap to deliver higher quality data, speed-to-insight, and advanced analytics and data visualization for our clients.” Apollo has made sizable investments in its platform since 2019 in anticipation of this launch. Its relationship with Frazier Healthcare Partners, in June 2022, has accelerated investment in these areas, with Frazier and Apollo sharing a vision for technological innovation within the healthcare data and insights market. The Frazier Data and AI Center of Excellence has been an instrumental partner in rapidly advancing these modern elements and realizing Apollo’s technology vision. Apollo Intelligence Apollo’s mission is to accelerate health innovation to improve life. In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry. In 2020, Apollo strengthened its global reach by acquiring Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions. Apollo provides access to 2 million healthcare stakeholders worldwide—including physicians, patients, caregivers, and allied healthcare professionals. Apollo’s 250+ employees support top global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.

Read More

DIGITAL HEALTHCARE

CarepathRx Health System Solutions and Evernorth Health Services Forge Strategic Partnership to Enhance Specialty Care for Patients

PRNewswire | June 02, 2023

CarepathRx Health System Solutions, a CarepathRx company and portfolio company of Nautic Partners (Nautic), and Evernorth Health Services, a subsidiary of The Cigna Group announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions, and health system relationships to improve, expand, and accelerate pharmacy care delivery for the growing number of patients with chronic and complex care needs. The CHSS and Evernorth partnership will deliver integrated specialty pharmacy care to CHSS' growing base of 600-plus hospitals, health systems, and physicians – helping diversify the services they offer to best support patients. This includes enhanced coordinated infusion services, virtual care capabilities, value-based care arrangements, and site of care flexibility. Evernorth's expansive suite of services, including Accredo's specialty care and pharmacy expertise and CuraScript SD's specialty medication distribution across 12,000 physicians, is highly complementary to CHSS' capabilities that help health systems expand in-house specialty pharmacies, infusion and polypharmacy services. "Forging deeper relationships with physicians and other specialty and infusion pharmacies – a critical point of care for people with chronic and complex needs – is a key priority as we work to increase access to care and improve affordability," said Eric Palmer, President and CEO, Evernorth. "Specialty care continues to be a focal point for hospital, health system, and physician partners, and our collaboration with CHSS is an important step in delivering on our commitment to bring them even more patient care services to improve overall outcomes." Together, over time, CHSS' and Evernorth's expertise will help enable simpler, faster connections to care for patients managing chronic and complex specialty conditions. As many of these patients need specialty or acute drug therapies, the partnership will focus on continuity of care for specialty drugs, management of infusion services across sites of care – from ambulatory to physician office to home settings – and value-based site-of-care strategies. The intent is to drive optimal patient treatment plans and deepen physician engagement, resulting in better patient experiences, more care extensions, and greater affordability. "At CarepathRx, we believe health systems, hospitals, and physicians play the most important roles in providing the best care to patients with chronic and complex diseases," said John Figueroa, Chairman and CEO, CarepathRx. "Through specialty and infusion pharmacy partnerships, CHSS has created a model for health systems to extend their reach to alternate sites of care and into the home. This partnership with Evernorth is truly unique and will accelerate CHSS' mission by creating payer-physician connections and leveraging Evernorth's specialty and care services." Centerview Partners acted as lead financial advisor and Cantor Fitzgerald is also acting as financial advisor to CarepathRx and Nautic. Kirkland & Ellis LLP acted as legal advisor to CarepathRx and Nautic. Greenhill & Co. acted as financial advisor to Evernorth. Wachtell, Lipton, Rosen & Katz and Quarles & Brady LLP acted as legal advisors to Evernorth. About CarepathRx CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical, quality, and financial results. Through the industry's most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient's complete healthcare journey. The company takes an enterprise approach, providing a powerful combination of technology, market-leading clinical pharmacy services, and wrap-around services that optimize pharmacy performance across the enterprise for fully integrated pharmacy operations, expanded healthcare services, improved ambulatory access, minimized clinical variation, and new health system revenue streams. Today, CarepathRx serves more than 25 health systems and 600 hospitals, with more than 1,500 employees nationwide.

Read More

Spotlight

PeriGen

PeriGen

PeriGen is the global leader in applying AI to perinatal care. It is the only technology company deploying FDA-cleared AI algorithms at the bedside, its software has been featured in numerous peer-reviewed publications and has been shown to help health systems significantly reduce unanticipated NIC...

Events

Resources

resource image

MEDICAL DEVICES, HEALTHCARE ANALYTICS

Tips for tailoring eConsent for Optimal Patient Centricity.

Whitepaper

resource image

MEDICAL DEVICES, HEALTHCARE ANALYTICS

Delivering new treatments faster with a data flow ecosystem

Whitepaper

resource image

MEDICAL DEVICES, HEALTHCARE ANALYTICS

Tips for tailoring eConsent for Optimal Patient Centricity.

Whitepaper

resource image

MEDICAL DEVICES, HEALTHCARE ANALYTICS

Delivering new treatments faster with a data flow ecosystem

Whitepaper

Events